Somewhat Positive Press Coverage Somewhat Unlikely to Affect Agenus (AGEN) Share Price

News headlines about Agenus (NASDAQ:AGEN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agenus earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.3978599993088 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern’s rankings:

AGEN stock traded up $0.01 during mid-day trading on Thursday, reaching $1.70. The company had a trading volume of 1,764,900 shares, compared to its average volume of 1,517,832. The company has a debt-to-equity ratio of -0.11, a quick ratio of 1.32 and a current ratio of 1.32. The stock has a market capitalization of $205.04 million, a price-to-earnings ratio of -1.38 and a beta of 1.62. Agenus has a one year low of $1.65 and a one year high of $6.19.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16. analysts predict that Agenus will post -1.57 EPS for the current fiscal year.

A number of equities research analysts have issued reports on the company. BidaskClub cut Agenus from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. ValuEngine upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Read More: Should I follow buy, hold and sell recommendations?

Insider Buying and Selling by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with's FREE daily email newsletter.

Leave a Reply